Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. The Results Are Not Shocking

Jeffrey J. Goldberger; Rod Passman

doi:10.1016/j.jacc.2009.08.018

Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. The Results Are Not Shocking

Jeffrey J. Goldberger, Rod Passman

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

The risk of sudden death is highest early after myocardial infarction (MI) and progressively declines over the ensuing 6 to 12 months. Nevertheless, several randomized clinical trials have failed to show a survival benefit for implantable cardioverter-defibrillators when implanted early after MI in high-risk patients. The etiology of this acute MI-sudden cardiac death paradox is unclear, but may be related to the changing nature of the substrate over the several month period after acute MI. Further investigation is needed to delineate the actual causes of death in the early post-MI period and which interventions can be implemented to reduce the increased rate of sudden death that is observed.

Original language	English (US)
Pages (from-to)	2001-2005
Number of pages	5
Journal	Journal of the American College of Cardiology
Volume	54
Issue number	22
DOIs	https://doi.org/10.1016/j.jacc.2009.08.018
State	Published - Nov 24 2009
Externally published	Yes

Keywords

implantable defibrillator
myocardial infarction
sudden death

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2009.08.018

Fingerprint Dive into the research topics of 'Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. The Results Are Not Shocking'. Together they form a unique fingerprint.

Cite this

@article{6e0ff5091f7e450eab4e778787b757e2,

title = "Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. The Results Are Not Shocking",

abstract = "The risk of sudden death is highest early after myocardial infarction (MI) and progressively declines over the ensuing 6 to 12 months. Nevertheless, several randomized clinical trials have failed to show a survival benefit for implantable cardioverter-defibrillators when implanted early after MI in high-risk patients. The etiology of this acute MI-sudden cardiac death paradox is unclear, but may be related to the changing nature of the substrate over the several month period after acute MI. Further investigation is needed to delineate the actual causes of death in the early post-MI period and which interventions can be implemented to reduce the increased rate of sudden death that is observed.",

keywords = "implantable defibrillator, myocardial infarction, sudden death",

author = "Goldberger, {Jeffrey J.} and Rod Passman",

year = "2009",

month = nov,

day = "24",

doi = "10.1016/j.jacc.2009.08.018",

language = "English (US)",

volume = "54",

pages = "2001--2005",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "22",

}

TY - JOUR

T1 - Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. The Results Are Not Shocking

AU - Goldberger, Jeffrey J.

AU - Passman, Rod

PY - 2009/11/24

Y1 - 2009/11/24

N2 - The risk of sudden death is highest early after myocardial infarction (MI) and progressively declines over the ensuing 6 to 12 months. Nevertheless, several randomized clinical trials have failed to show a survival benefit for implantable cardioverter-defibrillators when implanted early after MI in high-risk patients. The etiology of this acute MI-sudden cardiac death paradox is unclear, but may be related to the changing nature of the substrate over the several month period after acute MI. Further investigation is needed to delineate the actual causes of death in the early post-MI period and which interventions can be implemented to reduce the increased rate of sudden death that is observed.

AB - The risk of sudden death is highest early after myocardial infarction (MI) and progressively declines over the ensuing 6 to 12 months. Nevertheless, several randomized clinical trials have failed to show a survival benefit for implantable cardioverter-defibrillators when implanted early after MI in high-risk patients. The etiology of this acute MI-sudden cardiac death paradox is unclear, but may be related to the changing nature of the substrate over the several month period after acute MI. Further investigation is needed to delineate the actual causes of death in the early post-MI period and which interventions can be implemented to reduce the increased rate of sudden death that is observed.

KW - implantable defibrillator

KW - myocardial infarction

KW - sudden death

UR - http://www.scopus.com/inward/record.url?scp=71849085003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849085003&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2009.08.018

DO - 10.1016/j.jacc.2009.08.018

M3 - Review article

C2 - 19926004

AN - SCOPUS:71849085003

VL - 54

SP - 2001

EP - 2005

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 22

ER -